Items where Author is "John, N."

Article

(2025) First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis. Neurotherapeutics. p. 12. ISSN 1933-7213

(2025) Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis. JAMA neurology. ISSN 2168-6157 (Electronic) 2168-6149 (Print) 2168-6149 (Linking)

(2024) Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom. Journal of Medical Economics. pp. 109-125. ISSN 1369-6998

(2024) Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies. Journal of Neurology. pp. 472-485. ISSN 1432-1459 (Electronic) 0340-5354 (Print) 0340-5354 (Linking)

(2024) A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic. Journal of Neurology. p. 12. ISSN 0340-5354

(2023) Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. pp. 875-883. ISSN 1352-4585

(2023) Effect of high-efficacy therapy on the course of disability in paediatric-onset multiple sclerosis. Multiple Sclerosis Journal. pp. 103-105. ISSN 1352-4585

(2023) Predictors of treatment switching in the Big Multiple Sclerosis Data Network. Frontiers in Neurology. p. 10. ISSN 1664-2295

(2022) Early non-disabling relapses are associated with a higher risk of disability accumulation in people with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. pp. 947-950. ISSN 1352-4585